Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: December 6, 2017
Subject: Announcement of new Phase III clinical data supporting the safety and efficacy of Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in preventing shingles among adults who have undergone autologous haematopoietic stem cell transplant (auHSCT).
Key Financial Metrics
This filing is a current report regarding clinical trial results and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Results
The filing details the results of the ZOE-HSCT Phase III study, which evaluated Shingrix in immune-compromised patients (auHSCT recipients). Key findings include:
- Overall Efficacy: 68.17% [95%CI: 55.56 - 77.53] against shingles in subjects aged 18 and above.
- Efficacy in Older Adults: 67.34% [95% CI: 52.60 - 77.89] in subjects aged 50 and above.
- Complication Reduction: Reduced overall complications linked to shingles episodes by 77.76% [95% CI: 19.05% - 95.93%].
- Post-Herpetic Neuralgia (PHN): Vaccine efficacy for preventing PHN was 89.27% [95% CI: 22.54-99.76].
- Safety: No safety issues related to the vaccine were detected; the safety profile was clinically acceptable with severe adverse events similar between vaccine and placebo groups.
Outlook, Management Commentary, and Risks
Management Commentary: Emmanuel Hanon, Senior Vice President and Head of Vaccines R&D, noted that stem cell transplant recipients have substantially weakened immune systems, placing them at high risk for viral diseases. The results demonstrate the vaccine's ability to prevent shingles and complications with just two doses, addressing a significant unmet medical need.
Regulatory Status and Outlook:
- Shingrix is currently approved in the US and Canada for adults aged 50 and above.
- Regulatory reviews are underway in the European Union, Australia, and Japan.
- GSK is evaluating these results alongside other Phase III studies in immune-compromised populations to inform regulatory agencies and healthcare providers.
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in the company's Annual Report on Form 20-F for 2016.
Key Facts for Investor Verification
- Verify the timeline for regulatory submissions and potential label expansions for Shingrix in immune-compromised populations based on the ZOE-HSCT data.
- Confirm the commercial impact of expanding the addressable market for Shingrix to include auHSCT recipients, a population previously contraindicated for live-attenuated shingles vaccines.
- Monitor upcoming regulatory decisions in the EU, Australia, and Japan regarding the standard Shingrix approval for adults 50+.
- Review the full safety data regarding severe adverse events (SAEs) and potential immune-mediated diseases (pIMDs) in the context of the broader immune-compromised patient population.